about
Balancing intellectual monopoly privileges and the need for essential medicines'Linkage' pharmaceutical evergreening in Canada and AustraliaAssessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policySustainable fuel, food, fertilizer and ecosystems through a global artificial photosynthetic system: overcoming anticompetitive barriers.Toward a treaty on safety and cost-effectiveness of pharmaceuticals and medical devices: enhancing an endangered global public goodPractical virtue ethics: healthcare whistleblowing and portable digital technology.Will international human rights subsume medical ethics? Intersections in the UNESCO Universal Bioethics Declaration.Supporting whistleblowers in academic medicine: training and respecting the courage of professional conscience.Nanotechnology in global medicine and human biosecurity: private interests, policy dilemmas, and the calibration of public health law.Integrated research into the nanoparticle-protein corona: a new focus for safe, sustainable and equitable development of nanomedicines.Nanosilver and global public health: international regulatory issues.A methodological framework of preparing economic evidence for selection of medicines in the Chinese setting.The affordability of prescription medicines in Australia: are copayments and safety net thresholds too high?Trials and tribulations in the removal of dextropropoxyphene from the Australian Register of Therapeutic Goods.Hearing Australian Aboriginal voices on neglect and sustainability.Flexner's ethical oversight reprised? Contemporary medical education and the health impacts of corporate globalisation.Collaborative research trials: a strategy for fostering mental health protections in developing nations.Normative foundations of technology transfer and transnational benefit principles in the UNESCO Universal Declaration on Bioethics and Human Rights.Normative role for medical humanities.Sunscreen Safety: The Precautionary Principle, The Australian Therapeutic Goods Administration and Nanoparticles in SunscreensImpact of the Australia–US Free Trade Agreement on Australian medicines regulation and pricesArtificial photosynthesis as a frontier technology for energy sustainabilityTowards a Global Solar Fuels Project-Artificial Photosynthesis and the Transition from Anthropocene to SustainoceneHuman serum albumin binding to silica nanoparticles – effect of protein fatty acid ligandGoverning Planetary Nanomedicine: Environmental Sustainability and a UNESCO Universal Declaration on the Bioethics and Human Rights of Natural and Artificial Photosynthesis (Global Solar Fuels and Foods)Towards Global Artificial Photosynthesis (Global Solar Fuels): Energy, Nanochemistry, and GovernanceEmerging Technologies: Challenges for Health Care and Environmental Ethics and Rights in an Era of GlobalisationPolicy challenges of nanomedicine for Australia's PBSDecision-analytical modelling in health-care economic evaluationsToxicological and public good considerations for the regulation of nanomaterial-containing medical products
P50
Q21203916-A7D18356-7F28-4DAE-BEC8-5F6D9194E889Q21232002-8815A41F-63E2-4A9C-B743-C213C3CE4604Q24812956-0747C63B-5F59-4F7E-B80B-5CF9A52FF2BAQ28648389-99A7CFDD-0197-4CB7-8D60-A39B56E052BBQ28768386-BEF630E2-758B-43EE-8EB4-02F860692C88Q35428026-7496A38E-AEA9-4CD6-BB37-2FBCD19F3306Q35429267-5DB59530-A920-42A8-B53C-C58F41C61D1EQ35559566-38056045-7F01-48CC-8330-0A43F049963CQ37030936-43DB67CE-FC6C-470D-BFBA-E4E2222FE665Q37331805-99808A46-F802-4823-8213-DBA3A0348704Q37763154-8974F7C9-59FD-456F-BC82-D3AB4F7CAD7AQ37846853-4BB66290-EF56-43B9-8E7F-362949850552Q42680776-069D237C-F6C2-4BEB-850D-1B59B1D23003Q45167233-99FA8485-3E06-4998-85C4-4515BB382F3FQ50444897-9CA680A7-81A9-4633-8400-A3D7163B352BQ50956868-968F8F2E-4FDA-424A-8A3B-867B50D8E86FQ51930620-BA07B948-EDBF-4674-8FAD-FC5899267E10Q53106806-70352CBA-626D-4454-ACDF-1F96D53DBB6EQ53363275-F82F3E94-20EA-4631-A653-3391E0C2A01AQ55897700-FD1CE718-25E5-4025-B054-CCB6AEE98A90Q56115857-7D33C916-1786-4BEC-B68C-0FDC710A80D4Q56454834-95992890-AE55-447A-A46B-F5759B80BC39Q56673060-4C6B0523-DBA9-4C86-A6BC-7D11F0D199B9Q57742514-60999E47-3767-48F1-92C9-D12C13776BF0Q57742530-785AC6E6-00BE-4094-ABE7-E87CEE2E8174Q57742534-B5E62A18-4A8D-4E68-B946-EDFC4AFDC5A5Q57742536-8D7EF5D4-81F6-4E0C-8B70-49B9CEC74595Q57742552-245FCF32-EB74-4832-B392-B5E47054F2EFQ57742559-9C8248FE-C4C9-4729-935B-75FBFBB2AFD0Q57742564-EB195097-6EFD-44F5-A637-23BBB8913360
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Thomas Alured Faunce
@ast
Thomas Alured Faunce
@en
Thomas Alured Faunce
@es
Thomas Alured Faunce
@nl
Thomas Alured Faunce
@sl
type
label
Thomas Alured Faunce
@ast
Thomas Alured Faunce
@en
Thomas Alured Faunce
@es
Thomas Alured Faunce
@nl
Thomas Alured Faunce
@sl
altLabel
Tom Faunce; TA Faunce; Faunce TA; Thomas Alured Faunce; T.A. Faunce; Faunce T.A.
@en
prefLabel
Thomas Alured Faunce
@ast
Thomas Alured Faunce
@en
Thomas Alured Faunce
@es
Thomas Alured Faunce
@nl
Thomas Alured Faunce
@sl
P106
P1153
6602110179
P21
P31
P496
0000-0002-6767-6190